Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Baxter International (NY: BAX )

39.37 -0.44 (-1.11%)
Official Closing Price Updated: 7:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Baxter International

< Previous 1 2 3 4 5 6 7 Next >
“Jackets And Packets” Stock Market (And Sentiment Results)
Revenues continue to grow, Free Cash Flow recovering, Margins high, Stock Price subdued. 
Via Talk Markets
Medtronic Recalls Some Video Laryngoscopes Due To Increased Risk For Battery Overheat, Explosion
Medtronic recalls devices over battery risks that could lead to explosions and updates usage instructions. 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Rivian, Chipotle Mexican And Sirius XM Are Among Top 10 Large Cap Losers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio?
Ten large-cap stocks were the worst performers last week, with TME, MBLY, RIVN, CMG, LINE, SIRI, HSY, BAX, BR, and UTHR all seeing declines. 
Via Benzinga
Baxter Tumbles On $3.8 Billion Kidney Deal — Why Investors Expected More
The company is selling its Vantive Kidney Care business to Carlyle, a private equity investor in the medtech space. 
Via Investor's Business Daily
Baxter Seals $3.8B Deal With Carlyle For Its Kidney Care Segment
Baxter has agreed to sell its Kidney Care segment to Carlyle for $3.8 billion. Baxter will receive about $3.5 billion in cash, with net after-tax proceeds estimated at $3 billion. Post-sale, Baxter... 
Via Benzinga
The Latest Analyst Ratings For Baxter Intl
Via Benzinga
Assessing Baxter Intl: Insights From 4 Financial Analysts
Via Benzinga
How Is The Market Feeling About Baxter Intl?
Via Benzinga
BAX Stock Earnings: Baxter Intl Beats EPS, Beats Revenue for Q2 2024
BAX stock results show that Baxter Intl beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Baxter Lifts Annual Outlook After Strong Q2 Beat, Medical Devices Sales
Baxter surpasses Q2 expectations with adjusted EPS of $0.68 and sales of $3.812 billion. Sales rose 3% reported and 4% constant currency, driven by Pharmaceuticals, Medical Products, and Healthcare... 
Via Benzinga
3 Contrarian Stock Picks to Buy Against the Market Consensus
Discover three contrarian stock picks with strong fundamentals that defy current market trends and offer significant rebound potential. 
Via InvestorPlace
Carlyle's $4B Purchase Of Baxter's Kidney Division Backed By Ares And HPS Financing
Ares Management and HPS Investment Partners lead a $3 billion credit facility to support Carlyle's potential acquisition of Baxter's kidney-care division, highlighting the evolving role of private... 
Via Benzinga
AutoNation, Baxter International And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Unveiling 5 Analyst Insights On Baxter Intl
Via Benzinga
(BAX) - Analyzing Baxter Intl's Short Interest
Via Benzinga
A Glimpse Into The Expert Outlook On Baxter Intl Through 4 Analysts
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Bargain Bin Stocks with Millionaire-Maker Potential
Three bargain stocks with substantial upside from potential price-to-earnings multiple reratings and accretive buybacks. 
Via InvestorPlace
Carlyle Eyes $4B Acquisition Of Baxter's Kidney-Care Unit Vantive: Report
Carlyle is negotiating to acquire Baxter International's kidney-care spinoff, Vantive, in a $4 billion deal, including debt. The deal reflects a significant move in private-equity dealmaking and... 
Via Benzinga
“Cash Flow Is The Name Of The Game” Stock Market
Liquidity is becoming a problem and the Fed (and other Central Bankers) know it. Higher for longer is a luxury they can no longer afford. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
7 Deeply Undervalued Stocks to Buy Now or Regret Later
Unlock massive upside by buying these deeply undervalued stocks at fire-sale prices. These companies have staying power and could bounce back. 
Via InvestorPlace
3 Dividend Stocks For 10%+ Annual Returns
Buying undervalued dividend stocks with growth potential could lead to above-average returns. 
Via Talk Markets
3 Dividend Growth Stocks For Long-Term Returns
One way to measure the quality of a dividend stock is by its dividend history. Stocks with established histories of dividend growth may be likely to continue growing their dividends moving forward.... 
Via Talk Markets
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Fresenius SE's Future With Dialysis Company Unclear, Investors Seek Answers
Investors urge Fresenius SE to clarify its strategic plans for Fresenius Medical Care after recent deconsolidation. Despite holding a 32% stake, challenges like high dialysis patient mortality and... 
Via Benzinga
Why Is Nuvo Group (NUVO) Stock Up 200% Today?
Although prenatal care specialist Nuvo Group saw its shares soar on Monday, NUVO stock faces skepticism over its SPAC merger. 
Via InvestorPlace
The Big Split: 3 Stock Spinoffs Are Coming. Should You Buy?
Stock spinoffs can unlock shareholder value but management sometimes uses them to get rid of unwanted, slow-growing businesses. 
Via InvestorPlace
Why Is Medical Device Maker Baxter Stock Trading Lower On Thursday?
Baxter reports Q1 adjusted EPS at $0.65, up 10% Y/Y, surpassing expectations. Sales hit $3.59 billion, with 2% growth on a reported basis. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
BAX Stock Earnings: Baxter Intl Beats EPS, Beats Revenue for Q1 2024
BAX stock results show that Baxter Intl beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.